[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Bae SB, Lee KK, Kim JS, Lee JH, Lee NS, Lee GT, Park SK, Won JH, Baick SH, Hong DS, Lee DW, Park HS: A case of malignant proliferating trichilemmoma of the scalp with multiple metastases. Korean J Intern Med; 2001 Mar;16(1):40-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of malignant proliferating trichilemmoma of the scalp with multiple metastases.
  • We report a case of malignant proliferating trichilemmal tumor showing multiple distant metastases.
  • The patient was treated with cisplatin and etoposide combination chemotherapy and a partial response was achieved.
  • [MeSH-major] Brain Neoplasms / secondary. Head and Neck Neoplasms / pathology. Neoplasms, Basal Cell / secondary. Scalp. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Combined Modality Therapy. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neurosurgical Procedures / methods. Reoperation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11417304.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531700
  •  go-up   go-down


2. Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM: Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol Ther; 2009 Feb;8(3):289-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.
  • In the skin KLF4 is co-expressed with the nuclear receptors RARgamma and RXRalpha, and formation of the skin permeability barrier is a shared function of these three proteins.
  • We utilized a KLF4-transgenic mouse model of skin cancer in combination with cultured epithelial cells to examine functional interactions between KLF4 and retinoic acid receptors.
  • We tested retinoids in epithelial cell transformation assays, including an RAR-selective agonist (all-trans RA), an RXR-selective agonist (9-cis UAB30, rexinoid), and a pan agonist (9-cis RA).
  • Similarly as shown for other mouse models of skin cancer, rexinoid prevented skin tumor initiation resulting from induction of KLF4 in basal keratinocytes.
  • Rexinoid permitted KLF4 expression and KLF4-induced cell cycling, but attenuated the KLF4-induced misexpression of cytokeratin 1 in basal cells.
  • Neoplastic lesions including hyperplasia, dysplasia and squamous cell carcinoma-like lesions were prevented for up to 30 days.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1232-9 [16344269.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1283-98 [16564017.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] J Biochem. 2008 Sep;144(3):313-21 [18511453.001]
  • [Cites] Nat Genet. 2008 Sep;40(9):1130-5 [19165927.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):633-6 [11034212.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3402-13 [12093741.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8771-9 [12496248.001]
  • [Cites] J Med Chem. 2003 Aug 14;46(17):3766-9 [12904083.001]
  • [Cites] Cancer Lett. 2003 Nov 10;201(1):17-24 [14580682.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):341-51 [15093541.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1747-55 [15073042.001]
  • [Cites] Anal Biochem. 1987 Oct;166(1):49-54 [3674416.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 25;18(12):3587-96 [2194165.001]
  • [Cites] Mol Cell Biol. 1991 Mar;11(3):1724-8 [1825351.001]
  • [Cites] J Cell Biol. 1994 Nov;127(4):1085-96 [7525602.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cell. 1995 Dec 15;83(6):841-50 [8521508.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] FASEB J. 1996 Jul;10(9):940-54 [8801176.001]
  • [Cites] FASEB J. 1996 Jul;10(9):1002-13 [8801161.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6265-73 [9343387.001]
  • [Cites] Cancer Metastasis Rev. 1997 Sep-Dec;16(3-4):349-56 [9433644.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):29-35 [9456240.001]
  • [Cites] J Med Chem. 1998 May 7;41(10):1679-87 [9572893.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3149-55 [9784489.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5696-706 [10409758.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1491-500 [15674344.001]
  • [Cites] Eur J Cancer Prev. 2007 Jun;16(3):203-15 [17415091.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1250-60 [17301838.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):357-69 [17446857.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4489-98 [17297467.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10394-400 [16288030.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1401-8 [16357510.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1525-38 [16751185.001]
  • (PMID = 19197145.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089019-070009; United States / NCI NIH HHS / CA / CA127405-02; United States / NCI NIH HHS / CA / R01 CA127405-01; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / CA094030-05; United States / NCI NIH HHS / CA / CA089019-06A20009; United States / NCI NIH HHS / CA / R01 CA094030-05; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / P50 CA089019-070009; United States / NIAMS NIH HHS / AR / AR050948; United States / NCI NIH HHS / CA / P50 CA089019-06A20009; United States / NCI NIH HHS / CA / P50 CA89019; United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / R01 CA127405-02; United States / NCI NIH HHS / CA / R01 CA127405; United States / NCI NIH HHS / CA / CA127405-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fatty Acids, Unsaturated; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Naphthalenes; 0 / Receptors, Retinoic Acid; 0 / Recombinant Fusion Proteins; 0 / Retinoid X Receptor alpha; 0 / UAB 30; 0 / retinoic acid receptor gamma; 5688UTC01R / Tretinoin; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ NIHMS94168; NLM/ PMC2776760
  •  go-up   go-down


3. Tripp CS, Blomme EA, Chinn KS, Hardy MM, LaCelle P, Pentland AP: Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. J Invest Dermatol; 2003 Oct;121(4):853-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • COX-2 inhibitors, which demonstrate significant in vivo selectivity relative to COX-1, suppress both ultraviolet-induced epidermal tumor development and progression, suggesting that prostaglandin regulation of keratinocyte biology is involved in the pathogenesis of epidermal neoplasia.
  • Following acute ultraviolet exposure, COX-2 expression was predominantly induced in the basal keratinocyte layer coincident with an increase in keratinocyte proliferation and apoptosis.
  • Likewise, keratinocyte apoptosis was increased with COX-2 inhibition, particularly in the proliferating basal keratinocyte layer.
  • We hypothesize that selective COX-2 inhibition, as described herein, may lead to enhanced removal of ultraviolet-damaged keratinocytes, thereby decreasing malignant transformation in the epidermis.
  • [MeSH-major] Epidermis / cytology. Isoenzymes / metabolism. Keratinocytes / enzymology. Keratinocytes / radiation effects. Prostaglandin-Endoperoxide Synthases / metabolism. Skin Neoplasms / prevention & control
  • [MeSH-minor] Acute Disease. Animals. Cell Division / physiology. Cell Division / radiation effects. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / pharmacology. Female. Mice. Mice, Hairless. Skin Diseases / drug therapy. Skin Diseases / metabolism. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14632205.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR-46828
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


Advertisement
4. Basić-Jukić N, Bubić-Filipi L, Prgomet D, Djanić Hadzibegović A, Bilić M, Kovac L, Kastelan Z, Pasini J, Mokos I, Basić-Koretić M, Kes P: Head and neck malignancies in Croatian renal transplant recipients. Bosn J Basic Med Sci; 2010 Apr;10 Suppl 1:S37-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed a large series of renal transplant recipients to determine the incidence and outcome of patients with malignant changes located at the head and neck.
  • Demographic data, localization and disease outcome were evaluated in patients who developed cancer.
  • Twenty one patients (1.7%) developed 27 head and neck malignancies.
  • The average time from transplantation to development of cancer was 56.8 months.
  • Of cutaneous malignancies, 88.9% were basal cell carcinoma; one patient had Merkell-cell carcinoma and one patient developed squamous cell carcinoma.
  • Six cases of basocellular skin cancer were recorded in one fair-skin patient.
  • Two patients had post-transplant lymphoproliferative disorder occurring at the head and neck.
  • One patient had brain tumor.
  • Radical surgery, radiation, and/or chemotherapy were necessary in 33.3% of patients.
  • Careful skin examination and oral examination is mandatory for discovering cancer before dissemination.
  • Sirolimus is safe alternative to calcineurin-based immunosuppression in patients who developed head and neck malignancies.
  • [MeSH-major] Head and Neck Neoplasms / complications. Head and Neck Neoplasms / etiology. Kidney Transplantation / methods. Renal Insufficiency / therapy
  • [MeSH-minor] Brain Neoplasms / complications. Croatia. Follow-Up Studies. Humans. Immunosuppression. Lymphoproliferative Disorders / etiology. Mouth Neoplasms / complications. Skin Neoplasms / complications. Thyroid Neoplasms / complications. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prilozi. 2009 Dec;30(2):175-84 [20087258.001]
  • [Cites] Nephrol Dial Transplant. 1995;10 Suppl 1:74-80 [7617285.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):591-3 [8647617.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):107-10 [5009611.001]
  • [Cites] Semin Respir Infect. 1993 Sep;8(3):233-9 [8016484.001]
  • [Cites] Transplantation. 1993 Apr;55(4):742-7 [8475546.001]
  • [Cites] Acta Otolaryngol. 2008 Nov;128(11):1255-8 [18607958.001]
  • [Cites] Kidney Int. 2008 Jan;73(1):136 [18084267.001]
  • (PMID = 20433429.001).
  • [ISSN] 1840-4812
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


5. Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PA, Bazarbachi A: EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood; 2008 Apr 1;111(7):3770-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
  • Imiquimod is an immune response modifier currently used as a topical treatment of genital warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular tumors.
  • We developed more efficient killers from the same family of compounds that can induce apoptosis without the prominent pro-inflammatory response associated with imiquimod.
  • HTLV-I-associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis.
  • Using potentially achievable concentrations of EAPB0203, we demonstrate inhibition of cell proliferation, G2/M cell- cycle arrest, and induction of apoptosis in HTLV-I-transformed and HTLV-I-negative malignant T cells and fresh ATL cells, whereas normal resting or activated T lymphocytes were resistant.
  • EAPB0203 treatment significantly down-regulated the antiapoptotic proteins c-IAP-1 and Bcl-XL and resulted in a significant loss of mitochondrial membrane potential, cytoplasmic release of cytochrome c, and caspase-dependent apoptosis.
  • Moreover, in HTLV-I-transformed cells only, EAPB0203 treatment stabilized p21 and p53 proteins but had no effect on NF-kappaB activation.
  • These results support a potential therapeutic role for EAPB0203 in ATL and HTLV-I-negative T-cell lymphomas, either as a systemic or topical therapy for skin lesions.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Cell Division / drug effects. G2 Phase / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Quinoxalines / pharmacology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminoquinolines / adverse effects. Aminoquinolines / pharmacology. Aminoquinolines / therapeutic use. Cytochromes c / metabolism. Human T-lymphotropic virus 1 / metabolism. Humans. Inflammation / chemically induced. Inflammation / metabolism. Inflammation / pathology. Inhibitor of Apoptosis Proteins / antagonists & inhibitors. Inhibitor of Apoptosis Proteins / metabolism. Jurkat Cells. Lymphocyte Activation / drug effects. Membrane Potential, Mitochondrial / drug effects. NF-kappa B / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-X Protein / antagonists & inhibitors. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218850.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / EAPB0203; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Quinoxalines; 0 / Tumor Suppressor Protein p53; 0 / bcl-X Protein; 9007-43-6 / Cytochromes c; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  •  go-up   go-down


6. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exenteration is indicated in patients with malignant neoplasms of orbital contents.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • Combined surgeries are necessary for complete tumor removal.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Rhabdomyosarcoma / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


7. Büyükpamukçu M, Varan A, Yazici N, Akalan N, Söylemezoğlu F, Zorlu F, Akyüz C, Kutluk MT: Second malignant neoplasms following the treatment of brain tumors in children. J Child Neurol; 2006 May;21(5):433-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms following the treatment of brain tumors in children.
  • All of the patients were treated by surgery, chemotherapy, and/or radiotherapy.
  • Six patients developed second malignant neoplasms, and their clinical and histopathologic characteristics are reviewed in this article.
  • The second malignant neoplasms were diagnosed as non-Hodgkin lymphoma, myelodysplastic syndrome, basal cell carcinoma, malignant melanoma, Kaposi sarcoma, and high-grade neuroectodermal tumor.
  • The median latency time was 3.03 years (range 0.39-22.93 years).
  • The outcome varied according to the histopathologic type of the second tumor.
  • The patients who developed non-Hodgkin lymphoma and myelodysplastic syndrome died of progressive disease.
  • The patients with second skin neoplasms are alive as of the time of this writing.
  • The patient with Kaposi sarcoma developed one of the rare reported second malignant neoplasms following a primary brain tumor in childhood.
  • A wide spectrum of second malignant neoplasms was detected after treatment of primary brain tumors with surgery, radiotherapy, and chemotherapy.
  • Long-term follow-up is therefore necessary for the child who has survived a primary central nervous system tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioma / pathology. Glioma / therapy. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901454.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Eng TY, Boersma MG, Fuller CD, Goytia V, Jones WE 3rd, Joyner M, Nguyen DD: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol; 2007 Dec;30(6):624-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive review of the treatment of Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is an uncommon but malignant cutaneous neuroendocrine carcinoma with a high incidence of local recurrence, regional lymph node metastases, and subsequent distant metastases.
  • It usually occurs in sun-exposed areas in elderly people, many of whom have a history of other synchronous or metachronous sun-associated skin lesions.
  • Surgery is the mainstay of treatment.
  • The role of adjuvant therapy has been debated.
  • However, data from recent development support a multimodality approach, including surgical excision of primary tumor with adequate margins and sentinel lymph node dissection followed by postoperative radiotherapy in most cases, as current choice of practice with better locoregional control and disease-free survival.
  • Patients with regional nodal involvement or advanced disease should undergo nodal dissection followed by adjuvant radiotherapy and, perhaps, systemic platinum-based chemotherapy in most cases.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Lymph Node Excision. Lymphatic Metastasis. Prognosis. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091058.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 206
  •  go-up   go-down


9. Kazakov AA, Grishina EE, Tarantul VZ, Gening LV: Effect of human cell malignancy on activity of DNA polymerase iota. Biochemistry (Mosc); 2010 Jul;75(7):905-11
Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human cell malignancy on activity of DNA polymerase iota.
  • An increased level of mutagenesis, partially caused by imbalanced activities of error prone DNA polymerases, is a key symptom of cell malignancy.
  • To clarify the possible role of incorrect DNA polymerase iota (Pol iota) function in increased frequency of mutations in mammalian cells, the activity of this enzyme in extracts of cells of different mouse organs and human eye (melanoma) and eyelid (basal-cell skin carcinoma) tumor cells was studied.
  • In the presence of Mg2+, the enzyme was active only in cell extracts of mouse testicles and brain, whereas in the presence of Mn2+ the activity of Pol iota was found in all studied normal mouse organs.
  • It was found that in cell extracts of both types of malignant tumors (basal-cell carcinoma and melanoma) Pol iota activity was observed in the presence of either Mn2+ or Mg2+.
  • In the presence of Mn2+ the Pol iota activity in the basal-cell carcinoma exceeded 2.5-fold that in control cells (benign tumors from the same eyelid region).
  • In extracts of melanoma cells in the presence of either cation, the level of the enzyme activity was approximately equal to that in extracts of cells of surrounding tumor-free tissues as well as in eyes removed after traumas.
  • The distinctive feature of tissue malignancy (in basal-cell carcinoma and in melanoma) was the change in DNA synthesis revealed as Mn2+-activated continuation of DNA synthesis after incorrect incorporation of dG opposite dT in the template by Pol iota.
  • Among cell extracts of different normal mouse organs, only those of testicles exhibited a similar feature.
  • This similarity can be explained by cell division blocking that occurs in all normal cells except in testicles and in malignant cells.
  • [MeSH-major] Carcinoma, Basal Cell / enzymology. DNA-Directed DNA Polymerase / metabolism. Eye Neoplasms / enzymology. Lymphoma, B-Cell, Marginal Zone / enzymology. Melanoma / enzymology
  • [MeSH-minor] Animals. Cell Line, Tumor. Enzyme Activation / drug effects. Enzyme Activators / pharmacology. Humans. Magnesium / pharmacology. Manganese / pharmacology. Mice. Mice, Inbred C57BL. Mutation

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673215.001).
  • [ISSN] 1608-3040
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Activators; 42Z2K6ZL8P / Manganese; EC 2.7.7.- / DNA polymerase iota; EC 2.7.7.7 / DNA-Directed DNA Polymerase; I38ZP9992A / Magnesium
  •  go-up   go-down


10. Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol; 2008 Feb;13(1):33-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
  • BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, we tabulated data on patients with malignant melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
  • Because the International Union Against Cancer (UICC) TNM and stage classifications for malignant melanoma were changed substantially in 2002, analyses in the present investigation were performed according to the new classifications.
  • In addition, the numbers of patients with various kinds of skin malignancies, including not only malignant melanoma but also basal cell carcinoma, squamous cell carcinoma, mycosis fungoides, actinic keratosis, Bowen's disease, and Paget's disease, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
  • RESULTS: The nationwide survey of Japanese patients with malignant skin tumors from 1987 to 2001 showed that the most prevalent skin tumor was basal cell carcinoma, which increased year by year, followed by squamous cell carcinoma, and then by malignant melanoma.
  • The following results were obtained from the data for melanoma patients registered at major institutions from 1987 to 2001. (1) The overall 10-year survival rates for melanoma patients in each chronological group were ranked as: group C > B > A, although only the difference between groups C and A was statistically significant. (2) The male-to-female ratio ranged from 1: 0.97 to 1: 1.14, and the survival rate of female patients was higher than that of male patients (the 140-month survival rate was 70.6% in females and 60% in males). (3) Assessment of the age distribution showed that the number of patients increased rapidly from ages 40-49 years and reached a peak at around 60 years in all three groups. (4) The sole of the foot was the most common site of melanoma in both males and females, while melanomas on the lower limbs were also prevalent in females. (5) Acral lentiginous melanoma (ALM) was the most common type in all three groups, accounting for nearly 50% of the patients in each group.
  • The number of patients with superficial spreading melanoma (SSM) increased steadily over time and exceeded the number of patients with nodular melanoma (NM) in group C.
  • In group C, the overall survival rate of stage IV patients with a normal serum lactic dehydrogenase (LDH) level was higher than that of patients with elevated LDH values. (9) Evaluation of the effects of some therapeutic procedures (prophylactic lymph node dissection and chemotherapy with and without interferon-beta) on the survivals of patients with melanoma was inconclusive and suggested the need for more studies in this area.
  • CONCLUSION: In Japan, the number of patients with malignant skin tumors has increased year by year.
  • The prognosis of patients with advanced malignant melanoma remains extremely poor, but that of patients in stage III has shown an improvement.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):897-907 [8557445.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):139-50 [12851837.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):109-16 [11706778.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1484-91 [10717634.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Harefuah. 1995 Jun 15;128(12):745-51, 824 [7557679.001]
  • (PMID = 18307017.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


11. Badri T, Zeglaoui F, Kochbati L, Kooli H, El Fekih N, Fazaa B, Kamoun MR: [Multiple basal cell carcinomas following radiation therapy for nasopharyngeal cancer]. Presse Med; 2006 Jan;35(1 Pt 1):55-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple basal cell carcinomas following radiation therapy for nasopharyngeal cancer].
  • INTRODUCTION: Basal cell carcinoma (BCC) is a cutaneous, generally primary malignancy, most common among the elderly.
  • We report the case of a patient presenting numerous BCCs several years after radiation therapy for nasopharyngeal cancer and discuss the risk factors for this tumor and the role played by radiation in its genesis.
  • Eleven years earlier, she had had an undifferentiated nasopharyngeal carcinoma (T3N2M0), which was treated by neoadjuvant chemotherapy and then external radiation therapy.
  • Neither clinical nor radiological check up showed signs of basal cell nevus syndrome.
  • DISCUSSION: BCC is the most frequent malignant tumor.
  • Disorders that might promote or complicate BCC should be systematically sought in young patients, especially basal cell nevus syndrome.
  • We found no reports in the literature of BCC following radiation treatment for nasopharyngeal cancer, but the occurrence of these tumors in our patient suggests the need for close supervision in such cases.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Nasopharynx / pathology. Neoplasm Staging. Radiotherapy Dosage. Skin / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462665.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Ishii A, Nishiguchi T, Kitagawa T, Yagi M, Hakamada A, Isoda K, Kurokawa I, Hara K, Mizutani H: A case of epidermotropic metastatic malignant melanoma with multiple nodular lesions of the scalp. J Dermatol; 2005 Oct;32(10):821-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of epidermotropic metastatic malignant melanoma with multiple nodular lesions of the scalp.
  • Epidermotropic metastatic malignant melanoma (EMMM) is a form of metastatic malignant melanoma that has dermal cell nests with epidermotropism and specific histopathological features.
  • The tumors developed one year before consultation and increased in size simultaneously.
  • The tumor cells were located mainly in the dermis and partly in the basal layer of the epidermis.
  • The tumors did not respond to combination chemotherapy with dacarbazine, nimustine, vincristine, and interferon-beta.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Melanoma / pathology. Melanoma / secondary. Scalp. Skin Neoplasms / pathology


13. Karve SJ, Feldman SR, Yentzer BA, Pearce DJ, Balkrishnan R: Imiquimod: a review of basal cell carcinoma treatments. J Drugs Dermatol; 2008 Nov;7(11):1044-51
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: a review of basal cell carcinoma treatments.
  • Basal cell carcinoma (BCC) is regarded as the most prevalent malignant skin tumor in whites.
  • In recent years, an immune response modifier drug, imiquimod, has been approved in treating superficial BCC (sBCC).
  • The objective of the authors was to review the published literature to evaluate outcomes such as efficacy, safety, and quality of life associated with imiquimod treatment among patients with sBCC.
  • Future studies evaluating long term cost effectiveness of imiquimod treatment are warranted.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Neoplasms, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Humans. Mohs Surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Quality of Life

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110735.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 50
  •  go-up   go-down


14. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • All these tumors are benign and/or of low-grade malignancy, with the exception of malignant myoepithelioma.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • Similarities in morphology and biological behavior compared to patients with "triple-negative" (hormone receptor and Her2) monophasic sarcomatoid carcinomas and pure spindle cell sarcomas are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Female. Humans. Middle Aged


15. Szeimies RM: Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin; 2007 Jan;25(1):89-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
  • Basal cell carcinomas (BCCs) are the most common malignant tumors of the skin.
  • Treatment of BCCs should be chosen according to clinical type, tumor size, and location.
  • Methyl aminolevulinate (MAL) photodynamic therapy (PDT) has the potential to become a therapy with equal effectiveness to classical therapeutic modalities with an excellent cosmesis, but without complications like scar formation, requirement for grafts, need of repetitive treatments over longer time periods, or pigmentary changes.
  • MAL is licensed in Europe, Australia, New Zealand, and Brazil for the treatment of actinic keratoses, Bowen's disease, and nodular and superficial BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126746.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 19
  •  go-up   go-down


16. Yücel A, Cinar C, Aydin Y, Senyuva C, Güzel Z, Cetinkale O, Altintaŝ M: Malignant tumors requiring maxillectomy. J Craniofac Surg; 2000 Sep;11(5):418-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors requiring maxillectomy.
  • Seventy cases with malignant tumors requiring maxillary resection in the past 10 years were reviewed, retrospectively.
  • The primary site of tumor was adjacent skin in 53%, maxillary sinus or maxilla in 20%, palate and alveolar arch in 13%, lip and buccal mucosa in 13%, and mandible in 1% of the cases.
  • The most common histopathological diagnoses was squamous cell carcinoma (54%), followed by basal cell carcinoma (20%).
  • Major skin loss was present in majority of the patients.
  • Lining of the maxillary sinus defects was provided with split-thickness skin grafts.
  • Postoperative radiotherapy was performed in 32 patients and combined radiotherapy and chemotherapy in 12 patients.
  • Resection of the tumor with free surgical margins and appropriate evaluation of the surgical defect for the most suitable reconstruction are the mainstays of treatment of the midfacial tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Facial Neoplasms / surgery. Female. Humans. Lip Neoplasms / surgery. Male. Mandible / surgery. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Middle Aged. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery. Orbit Evisceration. Palatal Neoplasms / surgery. Palatal Obturators. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314064.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Guenova E, Lichte V, Hoetzenecker W, Woelbing F, Moehrle M, Roecken M, Schaller M: Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res; 2009 Aug;19(4):271-3
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
  • Immunosuppressed patients are at increased risk of skin cancer.
  • A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone.
  • The patient died of metastatic disease 3 months after the diagnosis was made.
  • Renal transplant recipients are at high risk of developing nonmelanocytic skin tumors when on immunosuppressive therapy with cyclosporine A.
  • Less common is the development of skin cancer during immunosuppression with azathioprine.
  • Latest reports show the increased incidence of malignant melanoma in immunosuppressed patients.
  • Our case illustrates the necessity of close dermatological surveillance of allograft recipients, to assure an early recognition of any malignant skin tumor and to reduce the risk of systemic metastatic disease.
  • [MeSH-major] Azathioprine / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Melanoma / etiology. Neoplasms, Multiple Primary / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Therapy, Combination. Early Detection of Cancer. Humans. Lymphatic Metastasis. Male. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Nodular melanoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550360.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; MRK240IY2L / Azathioprine
  •  go-up   go-down


18. Serrels B, Serrels A, Mason SM, Baldeschi C, Ashton GH, Canel M, Mackintosh LJ, Doyle B, Green TP, Frame MC, Sansom OJ, Brunton VG: A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis; 2009 Feb;30(2):249-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
  • The Src family tyrosine kinases are key modulators of cancer cell invasion and metastasis and a number of Src kinase inhibitors are currently in clinical development for the treatment of solid tumours.
  • We have investigated the role of Src in mouse skin, which is one of the most tractable models of epithelial homoeostasis and tumorigenesis.
  • We found that Src protein expression and activity was regulated during the normal hair cycle and was increased specifically during the proliferative anagen phase and also in response to the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA).
  • AZD0530, a selective Src inhibitor, prevented the TPA-induced proliferation of basal keratinocytes both in vivo and in vitro.
  • Moreover, treatment with AZD0530 reduced papilloma formation following the well-established 7,12-dimethylbenz(a)anthracene/TPA skin carcinogenesis protocol but did not inhibit the subsequent proliferation of the papillomas.
  • Furthermore, AZD0530 did not alter the malignant conversion of papillomas to squamous cell carcinoma suggesting a role for Src in early tumour development in the skin carcinogenesis model, rather than at later stages of tumour progression.
  • Src expression and activity were also seen in human actinic keratoses that are hyperproliferative pre-malignant skin lesions, indicating that Src may also play a role in the early stages of human skin tumour development.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Benzodioxoles / therapeutic use. Cell Transformation, Neoplastic / drug effects. Quinazolines / therapeutic use. Skin Neoplasms / prevention & control. src-Family Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Female. Humans. Keratinocytes / cytology. Keratinocytes / drug effects. Keratosis / metabolism. Male. Mice. Middle Aged. Papilloma / chemically induced. Papilloma / drug therapy. Precancerous Conditions / metabolism. Tetradecanoylphorbol Acetate

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060248.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601648; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Benzodioxoles; 0 / Quinazolines; 9KD24QGH76 / saracatinib; EC 2.7.10.2 / src-Family Kinases; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


19. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, Rumpler G, Landthaler M, Stolz W: Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res; 2001 Dec;11(6):587-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II.
  • We investigated the significance of Cox-II in the progression of malignant melanomas (MMs).
  • Using immunohistology we determined that Cox-II is not expressed in 70 benign and malignant melanocytic tumours.
  • Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) were also analysed as controls: the BCCs were consistently Cox-II negative (n = 11), whereas the SCCs showed moderate to strong Cox-II expression in 53% (n = 17).
  • Reverse transcription-polymerase chain reaction and Western blotting of MM cell lines and MM tissues confirmed the lack of Cox-II expression in MM.
  • However, in vitro the Cox-inhibiting non-steroidal anti-inflammatory drug (NSAID) sulindac sulphide (SIS) was significantly more effective in inducing apoptosis than sulindac sulphone (SOS), a derivative with a negligible effect on Cox (P < 0.01).
  • The SIS doses needed for the induction of apoptosis were not significantly different in MM cell lines versus a Cox-II-positive colon carcinoma cell line (HT29).
  • We conclude that Cox-II expression is not involved in the progression of MM, and NSAID-induced apoptosis in MM cell lines seems to follow pathways independent of Cox-II.
  • Nevertheless, Cox-II inhibitors are still candidates for therapy, though they act via an unknown mechanism.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Apoptosis / drug effects. Isoenzymes / metabolism. Melanoma / pathology. Prostaglandin-Endoperoxide Synthases / metabolism. Skin Neoplasms / pathology. Sulindac / analogs & derivatives. Sulindac / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Basal Cell / enzymology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Child. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / pharmacology. DNA Primers / chemistry. Disease Progression. Enzyme-Linked Immunosorbent Assay. Humans. Immunoenzyme Techniques. Membrane Proteins. Middle Aged. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11725205.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / DNA Primers; 0 / Isoenzymes; 0 / Membrane Proteins; 184SNS8VUH / Sulindac; 63231-63-0 / RNA; 6UVA8S2DEY / sulindac sulfide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K619IIG2R9 / sulindac sulfone
  •  go-up   go-down


20. Dummer R, Beyeler M, Morcinek J, Burg G: [Cutaneous neoplasms]. Praxis (Bern 1994); 2003 Sep 3;92(36):1470-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The skin is the organ most commonly affected by malignancies.
  • Various cancers of the skin show a dramatic increase in incidence over the last decades.
  • Epithelial skin tumors are most frequently, e.g., basal cell carcinoma and the squamous cell carcinoma with its precursors, the actinic keratoses.
  • Melanoma, which is extremely difficult to treat in advanced tumor stages, is dreaded.
  • Besides that, there are other epithelial malignant diseases, e.g.
  • Morbus Bowen and adnexal tumors originating from the skin appendices.
  • Mesenchymal malignant neoplasias such as Morbus Kaposi, angiosarcomas and other dermal sarcomas, are rare.
  • Since the majority of malignant neoplasms is removable and curable by a simple surgical intervention, the knowledge of the different skin tumors is essential for non-dermatologist.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Melanoma. Skin Neoplasms
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Biopsy. Bowen's Disease / diagnosis. Bowen's Disease / drug therapy. Bowen's Disease / radiotherapy. Bowen's Disease / surgery. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / surgery. Carcinoma, Merkel Cell / therapy. Clinical Trials as Topic. Combined Modality Therapy. Cryotherapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. HIV Infections / complications. Hemangiosarcoma / diagnosis. Humans. Immunotherapy. Keratosis / diagnosis. Keratosis / drug therapy. Keratosis / surgery. Lymph Node Excision. Lymphatic Metastasis. Lymphoma / classification. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / radiotherapy. Lymphoma / surgery. Male. Neoplasm Recurrence, Local. Photochemotherapy. Randomized Controlled Trials as Topic. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / surgery. Skin / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14526630.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 22
  •  go-up   go-down


21. Schön MP, Schön M: Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis; 2004 May;9(3):291-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod, the first member of the imidazoquinoline family of immune response modifiers, has proven good clinical efficacy against basal cell carcinomas and actinic keratoses in several independent studies.
  • In addition, there is recent evidence that imiquimod is also efficacious against other tumors such as cutaneous metastases of malignant melanoma or vascular tumors.
  • The net result of this proinflammatory activity is a profound tumor-directed cellular immune response.
  • However, recent experimental and clinical data indicate that imiquimod also possesses considerable direct pro-apoptotic activity against tumor cells both in vitro and in vivo.
  • The structural analogue, resiquimod, exhibited very limited, if any, such pro-apoptotic activity, possibly due to its lacking ability to enter the cell.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Animals. Carcinoma, Basal Cell / drug therapy. Caspases / metabolism. Cytochrome c Group / metabolism. Enzyme Activation. Humans. Melanoma / drug therapy. Mitochondria / enzymology. Models, Biological. Ointments. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / drug therapy. Vascular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15258460.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytochrome c Group; 0 / Ointments; 0 / Proto-Oncogene Proteins c-bcl-2; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  • [Number-of-references] 65
  •  go-up   go-down


22. Chow KC, Lu MP, Wu MT: Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J Dermatol Sci; 2006 Mar;41(3):205-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma.
  • Previous clinical studies have demonstrated the over-expression of DDH in various types of cancers, including cutaneous squamous cell carcinoma (SCC), and its correlation with tumor progression and grave prognosis.
  • OBJECTIVE: To investigate possible mechanisms for DDH's correlation with tumor progression and unfavorable prognosis.
  • METHODS: DDH expression in SCC A431 cell line was examined by quantitative real-time PCR and immunoblotting.
  • RESULTS: DDH was found highly expressed by SCC A431 cells, which was barely detectable in other normal or malignant cutaneous cells, including keratinocytes, fibroblast, and basal cell carcinoma cell line.
  • RNAi Inhibition of DDH expression in A431 cells led to increased sensitivity to UVB-induced apoptosis and cytotoxicity of bleomycin treatment.
  • CONCLUSION: DDH may play important roles in tumor progression of SCC via induction of apoptosis- and drug-resistance.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Oxidoreductases / biosynthesis
  • [MeSH-minor] Bleomycin / pharmacology. Caspase 3. Caspases / metabolism. Cell Line. Cell Line, Tumor. Disease Progression. Fibroblasts / metabolism. Humans. In Situ Nick-End Labeling. Keratinocytes / metabolism. Models, Statistical. Polycyclic Hydrocarbons, Aromatic / metabolism. Prognosis. RNA Interference. Skin Neoplasms / drug therapy. Skin Neoplasms / enzymology. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Ultraviolet Rays. Up-Regulation

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361083.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Tetrazolium Salts; 0 / Thiazoles; 11056-06-7 / Bleomycin; 298-93-1 / thiazolyl blue; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


23. Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst; 2003 Aug 6;95(15):1138-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.
  • BACKGROUND: The incidence of nonmelanoma skin cancer, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs) is increasing, representing a major medical and economic problem.
  • Imiquimod acts both indirectly, via cytokine-mediated stimulation of cellular immune responses, and directly, through unknown mechanisms against tumor cells.
  • METHODS: Apoptosis was assessed by enzyme-linked immunosorbent assay, western blot analysis, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays in five SCC cell lines, HaCaT cells (a spontaneously immortalized human keratinocyte cell line), and normal keratinocytes treated with imiquimod, with its analog resiquimod, or with neither.
  • Differences between treated and untreated cells and tumors were determined using a two-tailed Student's t test.
  • RESULTS: Imiquimod, but not resiquimod, induced apoptosis in all SCC cell lines and HaCaT cells.
  • This induction involved activation of several caspases and Bcl-2-dependent cytosolic translocation of cytochrome c but was independent of the membrane-bound death receptors Fas, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R1-R4 receptors, and tumor necrosis factor-R1 and -R2 receptors.
  • CONCLUSION: Imiquimod has the potential to induce apoptosis in skin cancer cells, possibly by circumventing mechanisms developed by malignant tumors to resist apoptotic signals.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Apoptosis / immunology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / immunology. Imidazoles / pharmacology. Immunologic Factors / pharmacology
  • [MeSH-minor] Blotting, Western. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / immunology. Caspase 3. Caspases / drug effects. Cytochrome c Group / drug effects. DNA Fragmentation / drug effects. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Humans. In Situ Nick-End Labeling. Keratinocytes / drug effects. Keratinocytes / immunology. Proto-Oncogene Proteins c-bcl-2 / drug effects. Receptors, Tumor Necrosis Factor / drug effects. Tumor Cells, Cultured. Up-Regulation / drug effects

  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902443.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytochrome c Group; 0 / Imidazoles; 0 / Immunologic Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Tumor Necrosis Factor; 99011-02-6 / imiquimod; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; V3DMU7PVXF / resiquimod
  •  go-up   go-down


24. Choudhary S, Nouri K, Elsaie ML: Photodynamic therapy in dermatology: a review. Lasers Med Sci; 2009 Nov;24(6):971-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy in dermatology: a review.
  • Photodynamic therapy (PDT) is used for the prevention and treatment of non-melanoma skin cancer.
  • Until recently, clinically approved indications have been restricted to actinic keratoses, nodular and superficial basal cell carcinoma, and, since 2006, Bowen disease.
  • PDT is also used for the treatment of non-malignant conditions such as acne vulgaris and leishmaniasis, as well as for treating premature skin aging due to sun exposure.
  • The production of reactive oxygen intermediates like singlet oxygen depends on the light dose applied as well as the concentration and localization of the photosensitizer in the diseased tissue.
  • Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.
  • Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient, despite the low level of invasiveness.
  • The excellent cosmetic results after treatment are beneficial, too.
  • [MeSH-major] Photochemotherapy / methods. Skin Diseases / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Laser Therapy / methods. Lasers, Dye / therapeutic use. Lasers, Semiconductor / therapeutic use. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] J Drugs Dermatol. 2009 Jun;8(6):562-8 [19537381.001]
  • [Cites] J Am Acad Dermatol. 2003 Jun;48(6):893-6 [12789181.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):634-7 [16780497.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2004 Dec;1(4):263-77 [25048431.001]
  • [Cites] Dermatol Surg. 2006 Jun;32(6):795-801; discussion 801-3 [16792644.001]
  • [Cites] Sci Am. 1988 Aug;259(2):68-75 [3064295.001]
  • [Cites] J Drugs Dermatol. 2004 Sep-Oct;3(5):548-51 [15552607.001]
  • [Cites] Cancer. 1997 Jun 15;79(12 ):2282-308 [9191516.001]
  • [Cites] Lasers Surg Med. 1995;17(1):2-31 [7564853.001]
  • [Cites] Actas Dermosifiliogr. 2008 Dec;99(10 ):779-87 [19091216.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] Acta Derm Venereol. 1994 Mar;74(2):117-9 [7911616.001]
  • [Cites] J Drugs Dermatol. 2008 Jul;7(7):627-32 [18664153.001]
  • [Cites] Dermatol Surg. 2002 Aug;28(8):742-4; discussion 744 [12174070.001]
  • [Cites] Photochem Photobiol. 2001 Aug;74(2):339-45 [11547574.001]
  • [Cites] J Dermatolog Treat. 2005;16(4):219-23 [16249142.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1308-14 [19416257.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Nov;22(11):1302-11 [18624836.001]
  • [Cites] Acta Derm Venereol. 2008;88(3):288-90 [18480938.001]
  • [Cites] Dermatol Ther. 2005 May-Jun;18(3):242-52 [16229725.001]
  • [Cites] Br J Dermatol. 2009 May;160(5):1066-74 [19222455.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1386-94 [9652753.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):407-14 [18221452.001]
  • [Cites] Lasers Surg Med. 2006 Jan;38(1):22-5 [16392149.001]
  • [Cites] Dermatol Surg. 2007 Jul;33(7):825-30 [17598848.001]
  • [Cites] J Photochem Photobiol B. 1999 Nov-Dec;53(1-3):53-9 [10672529.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] Lasers Surg Med. 2007 Mar;39(3):203-9 [17311325.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):030507 [18601524.001]
  • [Cites] Lasers Med Sci. 2002;17(3):173-86 [12181632.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] J Photochem Photobiol B. 2002 Nov;68(2-3):147-55 [12468210.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23 (5):550-5 [19415804.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1262-9 [17107399.001]
  • [Cites] Lasers Med Sci. 2004;18(4):179-83 [15042420.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Lasers Surg Med. 1999;25(1):51-9 [10421886.001]
  • [Cites] Ann Plast Surg. 2007 Nov;59(5):484-8 [17992139.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2007 Feb;23 (1):35-6 [17254035.001]
  • [Cites] Acta Derm Venereol. 1999 Nov;79(6):451-5 [10598759.001]
  • [Cites] J Invest Dermatol. 2006 Dec;126(12):2679-86 [16841035.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3):524-6 [16488310.001]
  • [Cites] Lasers Med Sci. 2004;19(3):139-49 [15503248.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):647-51 [16546587.001]
  • [Cites] J Photochem Photobiol B. 2000 Nov;58(2-3):149-55 [11233643.001]
  • [Cites] Br J Dermatol. 2007 Mar;156(3):516-20 [17300242.001]
  • [Cites] Photomed Laser Surg. 2005 Apr;23(2):202-5 [15910187.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):823-8 [16898905.001]
  • [Cites] Int J Dermatol. 2007 Nov;46(11):1180-4 [17988339.001]
  • [Cites] Acta Derm Venereol. 2008;88(5):480-3 [18779886.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):340-8 [2025186.001]
  • [Cites] J Drugs Dermatol. 2007 Oct;6(10):1010-6 [17966178.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Dermatol Surg. 2009 Apr;35(4):586-92 [19309347.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):387-94 [18280335.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2009 Feb;25(1):57-8 [19152520.001]
  • [Cites] Lasers Surg Med. 2007 Apr;39(4):302-10 [17457834.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] G Ital Dermatol Venereol. 2009 Feb;144(1):79-83 [19218913.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1997 Oct-Dec;13(5-6):181-5 [9542754.001]
  • (PMID = 19653060.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 68
  •  go-up   go-down


25. Kovach BT, Stasko T: Use of topical immunomodulators in organ transplant recipients. Dermatol Ther; 2005 Jan-Feb;18(1):19-27
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solid organ transplant recipients are a growing population at increased risk for the development of cutaneous premalignant and malignant lesions, resulting in significant morbidity and mortality.
  • Topical immunomodulators, in particular imiquimod, have shown efficacy in the management of multiple malignant, precancerous, and viral conditions.
  • The ability to locally induce an immune response, presumably against tumor and viral antigens, and induce apoptosis makes topical immunomodulators a promising therapeutic option in organ transplant recipients.
  • Although limited, data have begun to accumulate on the use of imiquimod in transplant patients for the management of superficial, nodular, and infiltrative basal cell carcinomas; in situ and invasive squamous cell carcinomas; condyloma acuminata; and common warts.
  • [MeSH-major] Aminoquinolines / immunology. Immunologic Factors / immunology. Organ Transplantation. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842609.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Immunologic Factors; 99011-02-6 / imiquimod
  • [Number-of-references] 68
  •  go-up   go-down


26. Osiecka B, Jurczyszyn K, Symonowicz K, Bronowicz A, Ostasiewicz P, Czapińska E, Hotowy K, Krzystek-Korpacka M, Gebarowska E, Izykowska I, Dziegiel P, Terlecki G, Ziółkowski P: In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester. Cell Mol Biol Lett; 2010 Dec;15(4):630-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester.
  • Photodynamic therapy (PDT) is a well-known method for the treatment of malignant tumors, and its principles have been well established over the past 30 years.
  • This therapy involves the application of a chemical called a photosensitizer and its subsequent excitation with light at the appropriate wavelength and energy.
  • Topical photodynamic therapy with aminolevulinic acid (5-ALA) is an alternative therapy for many malignant processes, including nonmelanoma skin cancers such as basal-cell carcinoma (BCC).
  • Our novel approach for this study was to use a liposomal formulation of 5-ALA and its methyl ester (commercially available as metvix) both in vitro and in vivo, and to check whether the liposome-entrapped precursors of photosensitizers can induce the expression of metalloproteinases (MMPs) in animal tumor cells and in other tissues from tumor-bearing rats and in selected cell lines in vitro.
  • We also checked whether the application of tissue inhibitors of matrix metalloproteinases (TIMPs) has any effect on MMPs in the above-mentioned experimental models, and if they can cause complete inhibition of MMP expression.
  • After the PDT in tumor-bearing rats, MMP-3 was expressed in the tumor cells with the highest intensity of staining in the tissues directly adjacent to the tumors, while MMP-2 and -9 were not found.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Cell Line, Tumor / drug effects. Liposomes. Matrix Metalloproteinases / metabolism. Photochemotherapy / methods. Photosensitizing Agents
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / enzymology. Breast Neoplasms / radiotherapy. Cell Survival / drug effects. Female. Humans. Isoenzymes / metabolism. Rats. Rats, Wistar. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20865364.001).
  • [ISSN] 1689-1392
  • [Journal-full-title] Cellular & molecular biology letters
  • [ISO-abbreviation] Cell. Mol. Biol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Liposomes; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


27. Wolf IH, Kodama K, Cerroni L, Kerl H: Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol; 2007 Jun;29(3):237-41
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
  • Topical imiquimod (IQ) is an effective treatment for genital warts and various malignant tumors of the skin.
  • We investigated the composition of the inflammatory cell infiltrate before, during, and after the treatment of 10 superficial cutaneous malignancies (melanoma in situ (n = 4), melanoma metastasis (n = 1), squamous cell carcinoma in situ (n = 4), and basal cell carcinoma (n = 1) with 5% IQ cream.
  • Immunophenotyping revealed in all cases during treatment an increased population of T-lymphocytes positive for CD3, CD4 and CD8, as well as a considerable number of cytotoxic cells (TIA-1+, granzyme B+) and plasmacytoid dendritic cells (CD 123+).
  • These findings further support previous investigations that the antitumor effects of IQ result from an enhanced cytotoxic T-cell mediated immune response and from the recruitment of plasmacytoid dendritic cells to the skin.
  • The population of infiltrative inflammatory cells was similar in all patients irrespective of the type of tumor.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Inflammation / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Bowen's Disease / chemistry. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma in Situ / chemistry. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Female. Humans. Hutchinson's Melanotic Freckle / chemistry. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Keratosis / drug therapy. Keratosis / metabolism. Keratosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519620.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Biomarkers, Tumor; 99011-02-6 / imiquimod
  •  go-up   go-down


28. Smith EB, Schwartz M, Kawamoto H, You X, Hwang D, Liu H, Scherr DS: Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol; 2007 Jun;177(6):2347-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
  • Imiquimod, a member of this drug family, is currently used as first line topical therapy for genital condyloma.
  • It recently showed clinical efficacy against several benign and malignant skin lesions, including actinic keratosis and basal cell carcinoma.
  • We hypothesized that imidazoquinolines have therapeutic potential against bladder cancer.
  • MATERIALS AND METHODS: The human and murine J82, T24, TCC-SUP (American Tissue Culture Collection, Manassas, Virginia) and MBT-2 bladder cancer cell lines were cultured in normal culture medium or medium supplemented with imidazoquinoline.
  • Effects on cell viability, apoptosis induction and cytokine production were evaluated.
  • In addition, the effects of imidazoquinoline on in vivo bladder tumor growth were determined via intravesical instillation in an orthotopic bladder tumor model in the mouse.
  • RESULTS: A dose dependent decrease in cell viability was observed in all tumor cell lines treated with imidazoquinoline.
  • In in vivo experiments most mice treated with imidazoquinoline showed only an intense inflammatory response with no evidence of tumor, while control mice showed tumor growth.
  • CONCLUSIONS: Imidazoquinolines have potent direct activity against bladder cancer cells by decreasing cell viability and inducing apoptosis and cytokine production.
  • Therefore, imidazoquinolines may have therapeutic potential as a synthetic intravesical agent against bladder cancer.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / pathology. Cell Line, Tumor / drug effects. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Culture Techniques. Cell Survival / drug effects. Cytokines / metabolism. Disease Models, Animal. Humans. Mice. Toll-Like Receptor 7 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509356.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


29. Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnait F, Rappersberger K, Pilarski P, Pehamberger H, European Cooperative Adjuvant Melanoma Treatment Study Group: Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol; 2005 Dec 1;23(34):8655-63
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
  • PURPOSE: The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines, but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.
  • We evaluated safety and efficacy of IFNalpha and isotretinoin compared with IFNalpha alone as adjuvant treatment in patients with primary malignant melanoma stage IIA and IIB.
  • PATIENTS AND METHODS: In a prospective, randomized, double-blind, placebo-controlled trial, 407 melanoma patients in stage IIA (301 patients) and IIB (106 patients) were randomly assigned to either IFNalpha and isotretinoin (isotretinoin group; 206 patients) or IFNalpha and placebo (placebo group; 201 patients) after excision of the primary tumor.
  • IFNalpha was administered three times a week at a dose of 3 million units subcutaneously for 24 months.
  • CONCLUSION: The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Isotretinoin / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Chemotherapy, Adjuvant. Disease-Free Survival. Double-Blind Method. Europe. Female. Humans. Hyperlipidemias / chemically induced. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life. Skin Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Dec 1;23(34):8559-63 [16260699.001]
  • (PMID = 16260701.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; EH28UP18IF / Isotretinoin
  •  go-up   go-down


30. Chan AL, Juarez M, Allen R, Volz W, Albertson T: Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatol Photoimmunol Photomed; 2005 Apr;21(2):72-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
  • BACKGROUND/PURPOSE: Mono-L-aspartyl chlorin e6 (NPe6) is a photosensitizer that exhibits chemical purity, absorption at 664 nm wavelength and may be useful in photodynamic therapy (PDT).
  • A single intravenous dose of Npe6 was administered to 14 cancer patients with superficial malignancies (basal cell carcinoma = 22 lesions, squamous cell cancer = 13 lesions, papillary carcinoma = 14 lesions).
  • The total light dose (range 25-200 J/cm2) depended on the tumor shape and size.
  • RESULTS: Four weeks post-PDT, 20 of 22 basal cell carcinoma tumors (91%) showed a complete response.
  • Eighteen of 27 other malignant cutaneous tumors showed a complete (n = 15/27, 56%) or partial (n = 3/27, 11%) response.
  • [MeSH-major] Photochemotherapy. Photosensitizing Agents / administration & dosage. Porphyrins / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752124.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; P4ROX5ELT2 / Talaporfin
  •  go-up   go-down


31. Rossi R, Puccioni M, Mavilia L, Campolmi P, Mori M, Cappuccini A, Reali EF, Cappugi P: Squamous cell carcinoma of the eyelid treated with photodynamic therapy. J Chemother; 2004 Jun;16(3):306-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the eyelid treated with photodynamic therapy.
  • The ocular tissues can be the site of a number of malignant tumors in adults.
  • Approximately 5% to 10% of all skin tumors occur in the eyelid.
  • Incidence studies indicate that basal cell carcinoma is the most frequent malignant eyelid tumor (90%) followed by squamous cell carcinoma (9%).
  • A 55-year-old man presented a squamous cell carcinoma (SCC) of 8 mm diameter, localized in the middle third of the lower eyelid, 3 mm under the eyelid margin on the eyelids.
  • The histopathologic examination of a biopsy specimen showed the typical features of squamous cell carcinoma.
  • Photodynamic therapy (PDT) with topical 5-aminolevulic acid (ALA) after Frost suture was employed.
  • Many therapeutic methods have been suggested for squamous cell carcinoma of the eyelid.
  • We consider photodynamic treatment of eyelid skin malignancies to be of great interest and it may represent an interesting future perspective for their management especially when surgical intervention cannot be tolerated by the patient.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Eyelid Neoplasms / drug therapy. Eyelid Neoplasms / pathology. Photochemotherapy / methods
  • [MeSH-minor] Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15330331.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


32. Stern RS, Bagheri S, Nichols K, PUVA Follow Up Study: The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol; 2002 Jul;47(1):33-9
Hazardous Substances Data Bank. PSORALEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In the general population, squamous cell carcinomas (SCCs) of the male genitalia are rare.
  • Ten years ago, we documented a significant dose-dependent increase in the risk of malignant genital neoplasms among men treated with psoralen plus ultraviolet A (PUVA).
  • Since that time, fewer cohort patients have used PUVA, and genital protection among PUVA users is likely to be frequent.
  • RESULTS: Twenty-four men (2.7%) had 51 genital neoplasms, including 10 patients with a first tumor after May 1, 1989 (the ending date for our 1990 report).
  • Multivariate models revealed the highest genital tumor risk among men with high-dose exposure to both PUVA and topical tar/ultraviolet B, with an incidence rate ratio of 4.5 (95% confidence interval, 1.3-16.1) compared with the low-dose exposure group.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Ficusin / adverse effects. Genital Neoplasms, Male / etiology. Genitalia, Male / pathology. PUVA Therapy / adverse effects. Psoriasis / drug therapy. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Age Distribution. Cohort Studies. Confidence Intervals. Dose-Response Relationship, Drug. Humans. Incidence. Male. Middle Aged. Probability. Prognosis. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12077578.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / N01 AR 44214
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] KTZ7ZCN2EX / Ficusin
  •  go-up   go-down


33. Karrer S, Szeimies RM, Hohenleutner U, Landthaler M: Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol; 2001;2(4):229-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
  • Tumor therapy is not a common indication for the use of lasers, as it is in the treatment of benign vascular skin lesions, since many alternative treatment modalities exist.
  • However, certain patients may benefit from laser therapy of premalignant and malignant skin tumors.
  • Skin tumors can be treated by laser excision, laser coagulation, laser vaporization, or photodynamic therapy (PDT).
  • PDT is a therapeutic approach based on the photosensitization of the target tissue by topical or systemic photosensitizers and subsequent irradiation with light from a laser or a lamp inducing cell death via generation of reactive oxygen species.
  • Laser therapy and PDT have shown good results in the curative treatment of actinic keratoses, superficial basal cell carcinoma, Bowen's disease and cheilitis actinica.
  • However, they are not recommended for primary malignant melanoma and invasive squamous cell carcinoma.
  • In some patients, lasers and PDT might also be used effectively for the palliative treatment of cutaneous metastases.
  • However, when treating invasive tumors with curative intention, one has to bear in mind the lack of histologic control and the limited depth of tissue penetration of most laser and PDT therapies.
  • [MeSH-major] Laser Therapy. Photochemotherapy. Precancerous Conditions / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aminolevulinic Acid / therapeutic use. Bowen's Disease / drug therapy. Bowen's Disease / surgery. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / surgery. Laser Coagulation. Leukoplakia, Oral / drug therapy. Leukoplakia, Oral / surgery. Male. Melanoma / drug therapy. Melanoma / surgery. Middle Aged. Palliative Care. Photosensitizing Agents / therapeutic use. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705250.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 59
  •  go-up   go-down


34. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology; 2006;213(3):204-14
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most therapies used for moderate to severe psoriasis are immunosuppressive.
  • Agents that depress immune function, including traditional psoriasis therapies, have been associated with an increased incidence of malignancies.
  • RESULTS: The efalizumab- and placebo-treated patients had similar incidence rates of malignancy, including lymphoproliferative disease, solid tumor, malignant melanoma and nonmelanoma skin cancer.
  • The incidence of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, in patients receiving efalizumab or placebo was elevated relative to the external databases.
  • CONCLUSIONS: These results suggest that efalizumab treatment does not increase a patient's risk for malignancy.
  • The difference observed with nonmelanoma skin cancer may be due to biases introduced by the clinical trial methodology.
  • Additional patient observation is necessary to ascertain whether a link exists between efalizumab therapy and nonmelanoma skin cancer above that normally observed in psoriasis patients.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Neoplasms / chemically induced. Psoriasis / drug therapy

  • Genetic Alliance. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033169.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Meta-Analysis
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / efalizumab
  •  go-up   go-down






Advertisement